BioSpace News Archive

Pharm Country

Outlook Therapeutics® Announces Validation of Marketing Authorization Application by the European Medicines Agency for ONS-5010 as a Treatment for Wet AMD

Outlook Therapeutics, Inc. today announced the validation of its Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for ONS-5010 / LYTENAVA™ (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD).

December 22, 2022
·
6 min read
Deals

AIkido Pharma Announces Name and Stocker Ticker Symbol Change to Dominari Holdings Inc. (Nasdaq: DOMH)

AIkido Pharma Inc. (NASDAQ: AIKI) (the “Company”) today announced that it has changed its name from AIkido Pharma Inc. to Dominari Holdings Inc. and its ticker symbol from “AIKI” to “DOMH.”

December 22, 2022
·
3 min read
Drug Development

Armata Pharmaceuticals Announces Completion of its Phase 1b/2a ‘SWARM-P.a.’ Study of Inhaled AP-PA02 in Cystic Fibrosis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection

Armata Pharmaceuticals, Inc. today announced that the last subject has completed the company’s Phase 1b /2a ‘SWARM- P.a.’ clinical trial of its lead candidate, AP-PA02, in cystic fibrosis (CF) subjects with chronic pulmonary Pseudomonas aeruginosa infection.

December 22, 2022
·
5 min read
Policy

Aptorum Group Limited Announces Results of 2022 Annual General Meeting of Shareholders

Regulatory News: Aptorum Group Limited announced the results of its 2022 annual general meeting of shareholders, which was held on December 21, 2022, in London.

December 22, 2022
·
5 min read
Business

PAVmed Partners with Novosound on Ultrasound Imaging Technology

PAVmed Inc. today announced that it has entered into a license option and joint research and development agreement with Novosound Ltd.

December 22, 2022
·
6 min read
Drug Development

Immunis Announces First-in-Human Injection of Secretome Product for Age and Disease-Related Immune Decline

Immunis, Inc., a private biotech company developing an innovative treatment for age and disease-related immune decline, announces its first-in-human injection of IMM01-STEM for its STEM-MYO Phase 1/2a clinical trial.

December 22, 2022
·
4 min read
BioMidwest

Omega Laboratories, Inc. Announces Launch of Urine Drugs of Abuse Testing in Ontario, Canada

Omega Laboratories, a leading provider of laboratory testing solutions, is proud to announce the launch of Urine Drugs of Abuse testing services in its state-of-the-art laboratory in Ontario, Canada.

December 22, 2022
·
3 min read
Biotech Beach

Neurocrine Biosciences Announces U.S. FDA Accepts Supplemental New Drug Application for Valbenazine as a Treatment for Chorea Associated with Huntington Disease

Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for valbenazine as a treatment for chorea associated with Huntington disease (HD).

December 22, 2022
·
7 min read
Biotech Beach

Envista Announces Participation in 41st Annual J.P. Morgan Healthcare Conference

Envista Holdings Corporation (NYSE: NVST) (“Envista”) today announced that the company will participate in the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 from 3:00 – 3:40 PM PT at the Westin St. Francis Hotel in San Francisco.

December 22, 2022
·
1 min read